Sanoculis

Executive Summary

Sanoculis Ltd. is an Israeli medtech company developing stentless, minimally invasive glaucoma surgery (MIGS) devices. Its flagship products, MINT® and MIMS®, create micro-channels in the trabecular meshwork to improve aqueous outflow and lower intraocular pressure, addressing a significant unmet need in glaucoma management. With a focused pipeline and a commercial-stage presence, the company targets the large and growing global glaucoma market, offering potential advantages over traditional stent-based approaches through simplified implantation and reduced foreign body response. The company has achieved commercial status, indicating initial market traction or regulatory clearance. Upcoming catalysts include regulatory milestones, clinical data readouts, and potential strategic partnerships. Given its innovative technology and the increasing adoption of MIGS procedures, Sanoculis is well positioned to capture market share. However, competition from established players and the need for robust clinical evidence remain key risks.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for MIMS Device75% success
• Q1 202712-Month Clinical Data from Pivotal Trial80% success
• Q2 2027Strategic Partnership with Major Ophthalmic Distributor50% success